Last week, readers were most interested in a story about Diasorin's preparation to enter the point-of-care molecular testing space with a benchtop instrument.

The target device includes a portable instrument and 30-minute, $5 assays requiring only small volumes of whole capillary blood.

NEW YORK – Tempus AI on Friday morning announced that its Q2 2025 revenues rose 90 percent year over year, driven by strong diagnostics sales. Tempus reported revenues of $314.6 million for the ...

The firm is aiming to accelerate growth in its molecular business by expanding menu and driving adoption of additional testing.

The test is compatible with lateral flow technology and could be used to provide tuberculosis testing in low-resource settings.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.

The Johns Hopkins University spinout's MycoMeia Aspergillus Assay is used to aid the diagnosis of the lung disease aspergillosis in immunocompromised patients.

The firm said it is in talks with payors about pilot programs and it expects to soon publish data on the use of its test to improve outcomes and reduce healthcare costs.

At ADLM, the company provided a preview of its Liaison Nes point-of-care PCR instrument that is complementary to the firm's Liaison Plex syndromic testing system.

The firm saw an increase in diagnostics solutions sales in the second quarter, particularly within its QuantiFeron and QiaStat-Dx businesses.

The firm anticipates lower than previously expected COVID test sales will be offset by shifts in trade policy and tariff mitigation efforts.